Alpert L, et al. - Through an institution's cohort of Inflammatory bowel disease-associated colorectal carcinomas (IBD-CRCs), the contributors investigated via molecular analysis, patients with IBD who underwent CRCs resection, in order to supplement emerging data on molecular alterations present in tumors. Mutations in TP53 in IBD-CRCs and in sporadic colorectal carcinomas were significant. Gene alterations with likely targeted therapies were rarely noticed exhibiting molecular differences in comparison to sporadic CRCs, directing different pathways of carcinogenesis for respective controls. A few common alterations were certain for both types of tumors. Expansion of therapeutic importance of IDH1 mutations in the future was guessed.